OptiMedica company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Acquired | Acquired

Total Raised




About OptiMedica

OptiMedica is a global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. Exclusively focused in the cataract therapeutic area, the company has developed the Catalys Precision Laser System to transform existing standards of care in cataract surgery. The company has also developed and commercialized the PASCAL Method of retinal photocoagulation, which was acquired by Topcon Corp. in August 2010.In August 2013, OptiMedica was acquired by Abbott Laboratories. The valuation of OptiMedica was $250 million. Other terms of the deal were not released.

OptiMedica Headquarter Location

1310 Moffett Park Drive

Sunnyvale, California, 94089,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing OptiMedica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

OptiMedica is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

OptiMedica Patents

OptiMedica has filed 178 patents.

The 3 most popular patent topics include:

  • Ophthalmology
  • Eye surgery
  • Vision
patents chart

Application Date

Grant Date


Related Topics




Ophthalmology, Eye surgery, Vision, Diseases of the eye and adnexa, Medical equipment


Application Date


Grant Date



Related Topics

Ophthalmology, Eye surgery, Vision, Diseases of the eye and adnexa, Medical equipment



Latest OptiMedica News

Cataract Surgery Devices And Equipment Global Market Report 2022

May 16, 2022

2022" - https://www.reportlinker.com/p06277184/?utm_source=GNW , NIDEK Co. Ltd., STAAR Surgical Company, and Johnson & Johnson. The global cataract surgery devices and equipment market is expected to grow from $5.95 billion in 2021 to $6.58 billion in 2022 at a compound annual growth rate (CAGR) of 10.6%. The market is expected to grow to $9.13 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The cataract surgery devices and equipment market consist of sales of cataract surgery devices and equipment and related services. Cataract surgery devices and equipment include instruments used for performing cataract surgeries such as small incision cataract surgery and extracapsular surgery in the treatment of cataracts, a condition in which the lens of the eye becomes progressively opaque, resulting in blurred vision. The main types of cataract surgery devices and equipment are intraocular lens (IOL), ophthalmic viscoelastic device (OVD), phacoemulsification equipment, and femtosecond laser equipment.An ophthalmic viscoelastic device (OVD) is used for performing cataract surgeries. The cataract surgery devices and equipment are used for various surgery types such as extracapsular cataract extraction, phacoemulsification, femtosecond laser, and others. These are used by end-users such as ophthalmology centers, hospitals, and clinics. North America was the largest region in the cataract surgery devices and equipment market in 2021.Asia Pacific was the second-largest region in cataract surgery devices and equipment market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The major growth driver for this industry has been the global aging population.In 2019, there were 703 million persons aged 65 years or over in the global population. This number is projected to double to 1.5 billion in 2050. The cases of cataracts in the geriatric population are also expected to increase in the same proportion. According to World Health Organization, the number of cataract cases is expected to increase by 78% by 2050 in the U.S. alone. This presents a huge market for cataract surgery equipment manufacturers shortly by expanding the customer base due to the fast-growing geriatric population. For instance, the population of China is getting older faster than anywhere else in the world, this presents a huge market for the cataract surgery device manufacturers in China. The major challenge that is faced by this industry is the low level of awareness about eye disorders, especially cataracts.Many people do not have proper knowledge about the symptoms of cataracts and do not get the treatment done. This leads to potential revenue loss for the cataract surgery device manufacturers because of the low number of end-users. For example, as per a study done by NCBI, out of 1552 respondents, 89.9% had heard of cataracts but only 42% were aware of any symptom of cataracts, low awareness of cataract symptoms acts as a major restraint for the cataract surgery equipment industry. The cataract surgery devices and equipment industry has witnessed many positive changes introduced by the market players, the most prominent one being the introduction of laser technology.Laser-assisted cataract surgery is used to gather information about the lens, to make the corneal incision, and for the opening in the lens capsule. The advent of laser technology has caused a significant impact on this industry by bringing in new levels of safety and accuracy and advancing cataract surgery.Femtosecond laser platforms have significantly contributed to the precision of cataract surgeries being performed and may soon surpass the traditional hand-held surgeries. For example, Abbott laboratories which lacked this technology, acquired Optimedica for $250 million to enter the laser cataract surgery devices market after witnessing the huge demand and benefits of laser technology. The ophthalmology and medical equipment industry are subject to numerous stringent regulations and the cataract surgery device equipment manufacturers are no exception. These manufacturers need to comply with several regulations of which the European Medical Device Directives and the U.S. Health Care Compliance is the most prominent one. The European Medical Device Directive requires a manufacturer to meet the harmonized standards for placing their devices in the European market. Similarly the U.S. Health Care Compliance has laid down certain guidelines related to standards of business conduct to be followed by the Pharmaceutical manufacturers. The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates the safety of medical devices in the UK, has issued an urgent notice to Carl Zeiss Meditec, for voluntarily recalling a small batch of its intraocular lenses (IOL). The recall was initiated after the manufacturer detected mislabelling of its IOL, Aaren Scientific EC-3 hydrophobic lens with the wrong dioptric power. Therefore, the manufacturers need to comply strictly with the correct labeling of dioptric power on the IOLs. In March 2019, Alcon, a company manufacturing cataract surgery devices acquired PowerVision for a deal amount of $285 million.This acquisition, will implement the growth of the advanced technologies of intraocular lenses and also help the patients with their needs regarding cataract surgery. Power vision, a US-based company, is a medical device company operating in cataract surgical devices. The countries covered in the cataract surgery devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia.

  • When was OptiMedica founded?

    OptiMedica was founded in 2004.

  • Where is OptiMedica's headquarters?

    OptiMedica's headquarters is located at 1310 Moffett Park Drive, Sunnyvale.

  • What is OptiMedica's latest funding round?

    OptiMedica's latest funding round is Acquired.

  • How much did OptiMedica raise?

    OptiMedica raised a total of $92.96M.

  • Who are the investors of OptiMedica?

    Investors of OptiMedica include Abbott, Alloy Ventures, Kleiner Perkins Caufield & Byers, DAG Ventures, BlackRock and 8 more.

  • Who are OptiMedica's competitors?

    Competitors of OptiMedica include Cornerstone Pharmaceuticals, Esperance Pharmaceuticals, Aegerion Pharmaceuticals, Presidio Pharmaceuticals, Ikaria and 12 more.

You May Also Like

Urigen Pharmacueticals

Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.


Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Albea Pharmaceuticals

Through a series of acquisitions, Albea Pharmaceuticals intends to build a rapidly growing, profitable, and pan-European pharmaceutical company with a portfolio of marketed products, a direct sales and marketing organization in the major European countries (UK, Germany, France, Italy and Spain), and a pipeline of products in various stages of clinical development.'

Drais Pharmaceuticals

Drais Pharmaceuticals, Inc. is dedicated to the development of therapeutic treatments that address unmet medical needs and provide significant benefits over currently available therapies.


ThyroChek is the only available rapid test for elevated TSH approved by the FDA. It is a rapid, qualitative test for elevated TSH, thyroid stimulating hormone, a clinical indicator of hypothyroidism. Screening Devices Canada is producing products for the thyroid health market in the United States which is a market valued at $1.2B annually.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.